Covid-19 ARDS Completed Phase 3 Trials for Tocilizumab (DB06273)

Also known as: COVID19 ARDS

IndicationStatusPhase
DBCOND0135643 (Covid-19 ARDS)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04678739Efficacy and Safety of Remdesivir and Tociluzumab for the Management of Severe COVID-19: A Randomized Controlled TrialTreatment